Business
Vor Appoints Biotech Finance Leader to BOD
Vor Appoints Biotech Finance Leader to BOD.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n RNS Number : 1484T\n PureTech Health PLC\n 16 July 2020\n \n \n \n \n 16 July 2020\n \n \n PureTech Health plc\n \n \n \n \n \n \n PureTech Founded Entity \n \n \n Vor Biopharma Appoints Daniella Beckman to its Board of Directors\n \n \n \n \n \n \n \n \n PureTech Health plc\n \n \n (LSE: PRTC) (\"PureTech\"\n \n or the \"Company\"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Vor Biopharma, today announced it has appointed Daniella Beckman to its Board of Directors. Ms Beckman is an experienced biotech finance leader who currently serves as chief financial officer at Tango Therapeutics. The appointment follows the hiring of Christopher Slapak, MD, as chief medical officer and the recent completion of a $110 million Series B financing round.\n \n \n \n \n \n \n The full text of the announcement from Vor is as follows:\n \n \n \n \n \n Vor Biopharma Appoints Daniella Beckman to its Board of Directors\n \n \n \n \n \n CAMBRIDGE, Mass., - July 16, 2020 - \n \n \n Vor Biopharma\n \n \n , an oncology company pioneering engineered haematopoietic stem cells (eHSCs) for the treatment of cancer, today announced the appointment of Daniella Beckman to its Board of Directors. The appointment of Ms Beckman, an experienced biotech finance leader who currently serves as Chief Financial Officer at Tango Therapeutics, follows the hiring of Christopher Slapak, MD, as Chief Medical Officer and the completion of a $110 million Series B financing round.\n \n \n \n \n \n \"Daniella is a fantastic addition to our Board of Directors and we are honored to have her join at this important time for our company,\" said Robert Ang, MBBS, MBA, Vor's President and Chief Executive Officer. \"Her expertise in financial strategy and operations will be of great value to us as we leverage our recent Series B funding round to further advance our \n lead product candidate VOR33 towards clinical trials and continue to build out our portfolio.\" \n \n \n \n \n \n Ms Beckman joins Vor with deep financial and operational experience across the biotechnology industry, having worked with both private and publicly traded companies throughout her career. At Tan...